Research Article
Propylene Glycol Caprylate-Based Nanoemulsion Formulation of Plumbagin: Development and Characterization of Anticancer Activity
Table 1
Solubility of plumbagin in lipid-based pharmaceutical excipients at 25°C.
| | Excipient | Plumbagin | | mg/ml | ±SD |
| | Capryol 90 (propylene glycol monocaprylate (type II) NF) | 94.6 | 0.4 | | Labrasol (caprylocaproyl macrogol-8 glycerides) | 125.0 | 1.2 | | Labrafil M 1944 CS (oleoyl macrogol-6 glycerides) | 82.1 | 0.5 | | Labrafac lipophile WL 1349 (caprylic/capric triglyceride IIG) | 89.4 | 0.1 | | Capmul MCM EP/NF (glycerol monocaprylocaprate, type I) | 92.0 | 0.6 | | Capmul PG-12 EP/NF (propylene glycol monolaurate) | 83.7 | 0.1 | | Glyceryl trioleate | 58.6 | 0.3 | | Peceol (glyceryl monooleate, type 40) | 52.0 | 0.1 | | Span 80 (Sorbitan monooleate) | 53.5 | 0.5 | | Span 85 (Sorbitan trioleate) | 57.9 | 0.1 |
|
|
